January 19, 2010:
Stem Cell Therapeutics Corp. (TSXV: SSS), $0.395, +0.06, 17.91%, is making gains today surpassing its 52 week-high of 0.34 and trading between 0.43 and 0.35 today on heavy volume. Stem Cell Therapeutics is a biotechnology company mainly focused on development and commercialization of drug-based therapies to treat diseases in the central nervous system. The company released some good news confirming that it has been advised by the Data Safety Monitoring Board that its second regularly scheduled safety analysis has been completed and the DSMB has recommended for the Phase IIb acute ischemic stroke trial to continue as per protocol.